Proinflammatory cytokine levels in patients with conversion disorder
dc.authorid | Caliyurt, Okan/0000-0002-0513-0619 | |
dc.authorwosid | Caliyurt, Okan/ABE-7339-2020 | |
dc.contributor.author | Tiyekli, Utkan | |
dc.contributor.author | Caliyurt, Okan | |
dc.contributor.author | Tiyekli, Nimet Dilek | |
dc.date.accessioned | 2024-06-12T10:58:27Z | |
dc.date.available | 2024-06-12T10:58:27Z | |
dc.date.issued | 2013 | |
dc.department | Trakya Üniversitesi | en_US |
dc.description.abstract | Objective: It was aimed to evaluate the relationship between proinflammatory cytokine levels and conversion disorder both commonly known as stress regulated. Method: Baseline proinflammatory cytokine levels-[Tumour necrosis factor alpha (TNF-alpha), Interleukin-1 beta (IL-1 beta), Interleukin-6 (IL-6)]-were evaluated with enzyme-linked immunosorbent assay in 35 conversion disorder patients and 30 healthy controls. Possible changes in proinflammatory cytokine levels were evaluated again, after their acute phase in conversion disorder patients. Results: Statistically significant decreased serum TNF-alpha levels were obtained in acute phase of conversion disorder. Those levels increased after acute conversion phase. There were no statistically significant difference observed between groups in serum IL-1 beta and (IL-6) levels. Conclusions: Stress associated with conversion disorder may suppress immune function in acute conversion phase and may have diagnostic and therapeutic value. | en_US |
dc.identifier.doi | 10.1111/j.1601-5215.2012.00676.x | |
dc.identifier.endpage | 143 | en_US |
dc.identifier.issn | 1601-5215 | |
dc.identifier.issue | 3 | en_US |
dc.identifier.pmid | 25287467 | en_US |
dc.identifier.scopus | 2-s2.0-84879899930 | en_US |
dc.identifier.scopusquality | Q2 | en_US |
dc.identifier.startpage | 137 | en_US |
dc.identifier.uri | https://doi.org/10.1111/j.1601-5215.2012.00676.x | |
dc.identifier.uri | https://hdl.handle.net/20.500.14551/20075 | |
dc.identifier.volume | 25 | en_US |
dc.identifier.wos | WOS:000320550800003 | en_US |
dc.identifier.wosquality | Q4 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.language.iso | en | en_US |
dc.publisher | Cambridge Univ Press | en_US |
dc.relation.ispartof | Acta Neuropsychiatrica | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Conversion Disorder | en_US |
dc.subject | Cytokine | en_US |
dc.subject | Interleukin-1 Beta | en_US |
dc.subject | Interleukin-6 | en_US |
dc.subject | Tumour Necrosis Factor Alpha | en_US |
dc.subject | Tumor-Necrosis-Factor | en_US |
dc.subject | Epstein-Barr-Virus | en_US |
dc.subject | Dissociative Disorder | en_US |
dc.subject | Somatoform Disorders | en_US |
dc.subject | Stress | en_US |
dc.subject | Immune | en_US |
dc.subject | Psychoneuroimmunology | en_US |
dc.subject | Benzodiazepines | en_US |
dc.subject | Glucocorticoids | en_US |
dc.subject | Sensitization | en_US |
dc.title | Proinflammatory cytokine levels in patients with conversion disorder | en_US |
dc.type | Article | en_US |